BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Biofuel
,
Valproic acid
,
rs7903146
,
IGF1
,
calcium channel activity
,
Influenza
,
Embryo
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
indole
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
PLEKHA6
SLC43A2
TET2
LGI4
SLC2A1
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
FISCHER_DREAM_TARGETS
cell periphery
vesicle
cytosol
KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Radioresistant cell lines exposed to single dose alpha particle and gamma ray exposure
Pancreatic cell lines treated with chromatin-targeting small molecules
Breast cancer MCF-7 cells treated with selective estrogen receptor modulators
Primary adipocyte responses to PPARgamma agonists
HHUA endometrial cancer cells gene expression after treatment with scytonemin
Explore Curated Studies Results
Literature
Most Relevant Literature
Discovery and biological characterization of 1-(1H-indol-3-yl)-9H-pyrido[3,4-b]indole as an aryl hyd…
QSAR and metabolic assessment tools in the assessment of genotoxicity.
5-Benz-yloxy-3-methyl-1-tosyl-1H-indole.
1-Ethyl-2-phenyl-3-[2-(tri-methyl-sil-yl)ethyn-yl]-1H-indole.
Electrochemical oxidation of nitrogen-heterocyclic compounds at boron-doped diamond electrode.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Midostaurin in Indolent Systemic Mastocytosis
Indolent Non Follicular Lymphomas Prognostic Project
Treatment of Indolent Systemic Mastocytosis With PA101
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Ly…
Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ